These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 25081050)

  • 21. Reactive Epstein-Barr virus-related polyclonal lymphoproliferative disorder in a patient with AIDS.
    Martin SI; Zukerberg L; Robbins GK
    Clin Infect Dis; 2005 Oct; 41(8):e76-9. PubMed ID: 16163622
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Epstein-Barr virus-related lymphoproliferative disorder, cytomegalovirus reactivation, and varicella zoster virus encephalitis during treatment of medulloblastoma.
    Ohta M; Taga T; Nomura A; Kato H; Takano T; Maruo Y; Takeuchi Y; Ishida M; Ohta S
    J Med Virol; 2011 Sep; 83(9):1582-4. PubMed ID: 21739449
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Epstein-Barr virus-driven lymphoproliferative disorder post-CAMPATH-1H (alemtuzumab) in refractory polymyositis.
    Cooles FA; Jackson GH; Menon G; Isaacs JD
    Rheumatology (Oxford); 2011 Apr; 50(4):810-2. PubMed ID: 21208978
    [No Abstract]   [Full Text] [Related]  

  • 24. [Epstein-Barr virus-associated post-transplant lymphoproliferative disorder diagnosed by the episode of intestinal perforation following allogeneic hematopoietic stem cell transplantation].
    Aimoto M; Yamane T; Inoue A; Momose D; Moriguchi-Aimoto R; Wada-Inoue E; Okamoto S; Koh H; Nakane T; Takeoka Y; Akahori-Nakamae M; Nishiki-Kosaka S; Terada Y; Nakamae H; Koh KR; Nakao T; Ohsawa M; Hino M
    Rinsho Ketsueki; 2010 Dec; 51(12):1775-80. PubMed ID: 21258188
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Posttransplant lymphoproliferative disease.
    Soltys K; Green M
    Pediatr Infect Dis J; 2005 Dec; 24(12):1107-8. PubMed ID: 16371875
    [No Abstract]   [Full Text] [Related]  

  • 26. Rituximab single agent in age-related Epstein-Barr virus associated B cell disorder complicated by autoimmune anemia and pure red cell aplasia.
    Del Principe MI; Cefalo M; Buccisano F; Anemona L; Sarlo C; Di Caprio L; De Santis G; Giacobbi E; Maurillo L; Postorino M; Del Poeta G; Amadori S; Venditti A
    Ann Hematol; 2014 Sep; 93(9):1611-2. PubMed ID: 24452366
    [No Abstract]   [Full Text] [Related]  

  • 27. Epstein-Barr Virus-related Posttransplant Lymphoproliferative Disorder in Children: A Single-institution Experience.
    Jaing TH; Wu CT; Chen SH; Wen YC; Chang TY; Chuang WY
    J Pediatr Hematol Oncol; 2016 Apr; 38(3):e133-6. PubMed ID: 26886374
    [TBL] [Abstract][Full Text] [Related]  

  • 28. EBV-positive mucocutaneous ulcer in organ transplant recipients: a localized indolent posttransplant lymphoproliferative disorder.
    Hart M; Thakral B; Yohe S; Balfour HH; Singh C; Spears M; McKenna RW
    Am J Surg Pathol; 2014 Nov; 38(11):1522-9. PubMed ID: 25007145
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sustained response to intrathecal rituximab in EBV associated Post-transplant lymphoproliferative disease confined to the central nervous system following haematopoietic stem cell transplant.
    Bonney DK; Htwe EE; Turner A; Kelsey A; Shabani A; Hughes S; Hughes I; Wynn RF
    Pediatr Blood Cancer; 2012 Mar; 58(3):459-61. PubMed ID: 21584931
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Treatment of post-transplant lymphoproliferative disorder with monoclonal CD20 antibody (rituximab) after heart transplantation.
    Zilz ND; Olson LJ; McGregor CG
    J Heart Lung Transplant; 2001 Jul; 20(7):770-2. PubMed ID: 11448808
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Metachronous B-cell and T-cell post-transplant lymphoproliferative disorders with features of chronic active Epstein-Barr virus infection.
    Liu ID; Tan PL; Tan CX; Isa MS; Lau PY; Yeo WS; Chaturvedi S; Villegas MS; Ng KH; Yap HK; Ng SB
    Am J Hematol; 2015 Oct; 90(10):E204-5. PubMed ID: 26178917
    [No Abstract]   [Full Text] [Related]  

  • 32. Epstein-Barr virus infection and lymphoproliferative disorder after hematopoietic cell transplantation.
    Zhong Y
    Clin J Oncol Nurs; 2012 Apr; 16(2):211-4. PubMed ID: 22459531
    [TBL] [Abstract][Full Text] [Related]  

  • 33. EBV lymphoproliferative disease of host origin after haploidentical stem cell transplantation.
    Kasow KA; Leung W; Horwitz EM; Woodard P; Handgretinger R; Hale GA
    Pediatr Blood Cancer; 2007 Nov; 49(6):869-72. PubMed ID: 16421900
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Use of rituximab in conjunction with immunosuppressive chemotherapy as a novel therapy for Epstein Barr virus-associated hemophagocytic lymphohistiocytosis.
    Balamuth NJ; Nichols KE; Paessler M; Teachey DT
    J Pediatr Hematol Oncol; 2007 Aug; 29(8):569-73. PubMed ID: 17762500
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Post-transplant lymphoproliferative disorders: from treatment to early detection and prevention?
    Bakker NA; van Imhoff GW
    Haematologica; 2007 Nov; 92(11):1447-50. PubMed ID: 18024391
    [No Abstract]   [Full Text] [Related]  

  • 36. Sequential treatment with rituximab followed by CHOP chemotherapy in adult B-cell post-transplant lymphoproliferative disorder (PTLD): the prospective international multicentre phase 2 PTLD-1 trial.
    Trappe R; Oertel S; Leblond V; Mollee P; Sender M; Reinke P; Neuhaus R; Lehmkuhl H; Horst HA; Salles G; Morschhauser F; Jaccard A; Lamy T; Leithäuser M; Zimmermann H; Anagnostopoulos I; Raphael M; Riess H; Choquet S; ;
    Lancet Oncol; 2012 Feb; 13(2):196-206. PubMed ID: 22173060
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficiency of antiviral therapy plus IVIG in a case of primary EBV infection associated PTLD refractory to rituximab, chemotherapy, and antiviral therapy alone.
    Trappe R; Riess H; Anagnostopoulos I; Neuhaus R; Gärtner BC; Pohl H; Müller HP; Jonas S; Papp-Vary M; Oertel S
    Ann Hematol; 2009 Feb; 88(2):167-72. PubMed ID: 18636261
    [No Abstract]   [Full Text] [Related]  

  • 38. Epstein-Barr virus-associated post-transplant lymphoproliferative disorders presented as interstitial pneumonia; successful recovery with rituximab.
    Kunitomi A; Arima N; Ishikawa T
    Haematologica; 2007 Apr; 92(4):e49-52. PubMed ID: 17562592
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Successful treatment of aggressive post transplant lymphoproliferative disorder using rituximab.
    O'Dwyer ME; Launder T; Rabkin JM; Nichols CR
    Leuk Lymphoma; 2000 Oct; 39(3-4):411-9. PubMed ID: 11342323
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Post-transplant lymphoproliferative disease and other Epstein-Barr virus diseases in allogeneic haematopoietic stem cell transplantation after introduction of monitoring of viral load by polymerase chain reaction.
    Kinch A; Oberg G; Arvidson J; Falk KI; Linde A; Pauksens K
    Scand J Infect Dis; 2007; 39(3):235-44. PubMed ID: 17366054
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.